Ignite Creation Date:
2025-12-25 @ 2:20 AM
Ignite Modification Date:
2025-12-28 @ 12:04 AM
Study NCT ID:
NCT05950334
Status:
COMPLETED
Last Update Posted:
2025-08-22
First Post:
2023-07-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Sponsor:
Fate Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-16
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06-30
Completion Date Type:
ACTUAL
First Submit Date:
2023-07-10
First Submit QC Date:
None
Study First Post Date:
2023-07-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-18
Last Update Post Date:
2025-08-22
Last Update Post Date Type:
ACTUAL